Anti-SLAMF6/NTB-A Antibody, clone NT-7

SLAM family member 6 (UniProt: Q96DU3; also known as Activating NK receptor, NK-T-B-antigen (NTB-A), CD352) is encoded by the SLAMF6 (also known as KALI) gene (Gene ID: 114836) in human. SLAMF6 belongs to the 7-member signaling lymphocytic activation molecule family (SLAMF) of receptors broadly expressed in hematopoietic cells. SLAM receptors triggered by homo or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. SLAMF members carry one or more copies of immunoreceptor tyrosine-based switch motif or ITSM (T-X-Y-X-X-[VI]) in their cytoplasmic tails. Upon phosphorylation on the tyrosine residue, ITSM mediates the recruitment of SH2 domain-containing signaling molecules such as SLAM-associated protein (SAP), including SAP in T-, NK, and NK T-cells, EAT-2A and EAT-2B (murine) in NK cells and APCs. SLAMF6/NTB-A is predominantly localized to the cell membrane and is a single-pass type I membrane protein and is synthesized with a signal peptide sequence (aa 1-21), the removal of which yields the mature SLAMF6 with an extracellular domain (aa 22-226), a transmembrane domain (aa 227-247) and, a cytoplasmic domain (aa 248-331). Its expression is primarily observed in cells of the immune system. SLAMF6/NTB-A is a receptor on the surfaces of human NK, T, and B cells, mediating a signal whose malfunction may be involved in X-linked lymphoproliferative disease. Studies show that NTB-A is its own ligand and homophilic interaction of NTB-A enhances NK cell cytotoxicity and influences NK cell proliferation and IFN- secretion. It is also suggested that NTB-A is an interlymphocyte signaling molecule, which serves to orchestrate the activities of immune cells. Dysregulation of SLAMF6 signaling is associated with autoimmune conditions such as systemic lupus erythematosus (SLE), where it can contribute to abnormal immune cell activation. (Ref.: Flaig, R.M., et al. (2004). J Immunol. 172(11):6524-7; Stark, S., et al. (2005). J Immunol Methods. 296(1-2):149-58; Messmer, B., et al. (2006). J Immunol. 176(8):4646-50).

Recombinant fragment from extracellular domain of human SLAMF6/NTB-A.

Quality Control Testing

Evaluated by Flow Cytometry in Human peripheral blood mononuclear cells (PBMC).

Flow Cytometry Analysis: 1.0ug of this antibody detected SLAMF6/NTB-A in one million Human peripheral blood mononuclear cells (PBMC).

Tested Applications

ELISA: A representative lot detected NTB-A/CD352 in ELISA application (Stark, S., et al. (2005). J Immunol Methods. 296(1-2):149-58).

Flow Cytometry Analysis: A representative lot detected NTB-A/CD352 in Flow Cytometry application (Flaig, R.M., et al. (2004). J Immunol. 172(11):6524-7; Messmer, B., et al. (2006). J Immunol. 176(8):4646-50).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone NT-7 is a mouse monoclonal antibody that specifically detects SLAMF6/NTB-A. It targets an epitope within the extracellular domain.

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

1.0 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommended storage: +2°C to +8°C.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.